On this page
Fluocinonide
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 212976-001 | FLUOCINONIDE | OINTMENT | FLUOCINONIDE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | November 26, 2019 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260417). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS The topical corticosteriods are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneiform Eruptions Hypopigmentation Perioral Dermatitis Allergic Contact Dermatitis Maceration of the Skin Secondary Infection Skin Atrophy Striae Miliaria To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% are intended for topical administration. The active component in each is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-. It has the following chemical structure: Fluocinonide Cream USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated cream base consisting of citric acid, glycerin, 1,2,6-hexanetriol, polyethylene glycol-3350, polyethylene glycol-8000, propylene glycol and stearyl alcohol. This white cream vehicle is greaseless, non-staining, anhydrous and completely water miscible. The base provides emollient and hydrophylic properties. Fluocinonide Cream USP, 0.05% (Emulsified Base) contains fluocinonide 0.5 mg/g in a water-washable aqueous emollient base of cetyl alcohol, citric acid (anhydrous), mineral oil, polysorbate 60, propylene glycol, purified water, sorbitan monostearate, stearyl alcohol and white petrolatum. Fluocinonide Gel USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated gel base consisting of carbomer 940, edetate disodium, propyl gallate, propylene glycol, sodium hydroxide (to adjust pH) and purified water. This clear, colorless, thixotropic vehicle is greaseless, non-staining and completely water miscible. Fluocinonide Ointment USP, 0.05% contains fluocinonide 0.5 mg/g in a specially formulated ointment base consisting of glyceryl monostearate, propylene carbonate, propylene glycol, white petrolatum and white wax. It provides the occlusive and emollient effects desirable in an ointment. In the Fluocinonide Cream USP, 0.05%, Fluocinonide Gel USP, 0.05%, and Fluocinonide Ointment USP, 0.05% formulations, the active ingredient is totally in solution. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Fluocinonide Cream USP, 0.05% is supplied in 15 g (NDC 51672-1253-1), 30 g (NDC 51672-1253-2), 60 g (NDC 51672-1253-3) and 120 g (NDC 51672-1253-4) tubes. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Fluocinonide Cream USP, 0.05% (Emulsified Base) is supplied in 15 g (NDC 51672-1254-1), 30 g (NDC 51672-1254-2) and 60 g (NDC 51672-1254-3) tubes. Store at controlled room temperature. Avoid excessive heat, above 40°C (104°F). Fluocinonide Gel USP, 0.05% is supplied in 15 g (NDC 51672-1279-1), 30 g (NDC 51672-1279-2) and 60 g (NDC 51672-1279-3) tubes. Store at 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature]. Fluocinonide Ointment USP, 0.05% is supplied in 15 g (NDC 51672-1264-1), 30 g (NDC 51672-1264-2) and 60 g (NDC 51672-1264-3) tubes. Store at 20°-25°C (68°-77°F). Avoid temperature above 30°C (86°F).
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FLUOCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-2337-1 | 63629-2337 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-2337-1) / 60 g in 1 TUBE | April 19, 2021 |
| 63629-2338-1 | 63629-2338 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-2338-1) / 30 g in 1 TUBE | April 19, 2021 |
| 63629-2339-1 | 63629-2339 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-2339-1) / 15 g in 1 TUBE | April 19, 2021 |
| 72162-1972-2 | 72162-1972 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1972-2) / 15 g in 1 TUBE | February 2, 2024 |
| 72162-1972-3 | 72162-1972 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1972-3) / 30 g in 1 TUBE | February 2, 2024 |
| 72162-1972-6 | 72162-1972 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1972-6) / 60 g in 1 TUBE | February 2, 2024 |
| 68071-2202-5 | 68071-2202 | NuCare Pharmaceuticals,Inc. | 1 TUBE in 1 CARTON (68071-2202-5) / 15 g in 1 TUBE | June 25, 2020 |
| 68788-8554-6 | 68788-8554 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8554-6) / 60 g in 1 TUBE | November 20, 2023 |
| 51672-1264-1 | 51672-1264 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1264-1) / 15 g in 1 TUBE | June 30, 1999 |
| 51672-1264-2 | 51672-1264 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1264-2) / 30 g in 1 TUBE | June 30, 1999 |
| 51672-1264-3 | 51672-1264 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1264-3) / 60 g in 1 TUBE | June 30, 1999 |
| 0093-0264-15 | 0093-0264 | Teva Pharmaceuticals USA, Inc. | 1 TUBE in 1 CARTON (0093-0264-15) / 15 g in 1 TUBE | May 1, 1992 |
| 0093-0264-30 | 0093-0264 | Teva Pharmaceuticals USA, Inc. | 1 TUBE in 1 CARTON (0093-0264-30) / 30 g in 1 TUBE | May 1, 1992 |
| 0093-0264-92 | 0093-0264 | Teva Pharmaceuticals USA, Inc. | 1 TUBE in 1 CARTON (0093-0264-92) / 60 g in 1 TUBE | May 1, 1992 |
| 70700-146-15 | 70700-146 | Xiromed LLC | 1 TUBE in 1 CARTON (70700-146-15) / 15 g in 1 TUBE | December 9, 2019 |
| 70700-146-16 | 70700-146 | Xiromed LLC | 1 TUBE in 1 CARTON (70700-146-16) / 30 g in 1 TUBE | December 9, 2019 |
| 70700-146-17 | 70700-146 | Xiromed LLC | 1 TUBE in 1 CARTON (70700-146-17) / 60 g in 1 TUBE | December 9, 2019 |
| 63629-2337 | 63629-2337 | Bryant Ranch Prepack | — | December 9, 2019 |
| 63629-2338 | 63629-2338 | Bryant Ranch Prepack | — | December 9, 2019 |
| 63629-2339 | 63629-2339 | Bryant Ranch Prepack | — | December 9, 2019 |
| 72162-1972 | 72162-1972 | Bryant Ranch Prepack | — | December 9, 2019 |
| 68071-2202 | 68071-2202 | NuCare Pharmaceuticals,Inc. | — | May 1, 1992 |
| 68788-8554 | 68788-8554 | Preferred Pharmaceuticals Inc. | — | November 20, 2023 |
| 51672-1264 | 51672-1264 | Sun Pharmaceutical Industries, Inc. | — | June 30, 1999 |
| 0093-0264 | 0093-0264 | Teva Pharmaceuticals USA, Inc. | — | May 1, 1992 |
| 70700-146 | 70700-146 | Xiromed LLC | — | December 9, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.